Medical Condition News

RSS

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

FOXO3a protein stimulates cancer development

In a biological rendition of fiction's Strange Case of Dr. Jekyll and Mr. Hyde, researchers from the Mayo Clinic campus in Florida and Harvard Medical School have found that a protein thought to protect against cancer development can actually spur the spread of tumors.

4 Sep 2009

Genetic cause of progressive hearing loss discovered

A team led by scientists from The Scripps Research Institute has discovered a genetic cause of progressive hearing loss. The findings will help scientists better understand the nature of age-related decline in hearing and may lead to new therapies to prevent or treat the condition.

4 Sep 2009

Type 2 diabetic people not consuming healthy diets

People with type 2 diabetes are not consuming sufficiently healthy diets and could benefit from ongoing nutritional education and counseling, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.

4 Sep 2009

LearningRx teaches parents on how to improve their kids' attention

September is National Attention Deficit Hyperactivity Disorder (ADHD) Awareness Month. And, more than 60 LearningRx franchisees are showing parents how to increase the three types of attention skills.

4 Sep 2009

RanBP9 protein targeted for developing new Alzheimer's drugs

"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.

3 Sep 2009

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

Optimized turmeric extracts may prevent memory loss

scientists with HerbalScience Group LLC, working with researchers from other organizations and medical institutions, conducted an in-depth study of optimized turmeric extracts, demonstrating that key bioactives in the botanical extracts inhibit aggregation and release of amyloid, a protein fragment considered a prime causal suspect in Alzheimer's disease.

3 Sep 2009

Ethical Alternative Products launches the OmniFlex joint support formula

Ethical Alternative Products has launched OmniFlex, a unique joint support formula combining five highly researched ingredients shown specifically to positively impact joint structure and function in easy-to-swallow soft-gel capsules.

3 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

Damprid's recommendations for tackling seasonal allergy

For America’s 60 million seasonal allergy sufferers, fall can be one of the most difficult times of year as ragweed begins to release its pollen into the air and mold and fungus spores increase due to the decay of leaves and other plants. Each ragweed plant produces one billion pollen grains per average season. This generally continues until the first frost, usually in October.

3 Sep 2009

Beijing Rain and Earth Technology to provide cheaper blood dialysis in China

RainEarth Inc. (OTC Bulletin Board: RNER; "the Company") announced that in the second quarter of 2009, the Xinhua News Agency publicized the creation of "Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical and Health Care System" ("Opinion").

3 Sep 2009

SRC raises funds through concert to help autistic children

The Sensory Research Center (SRC) held its first benefit, dessert and silent auction concert featuring LA Collaboration on the last week of August 2009. SRC Founder, Jennifer Hoffiz, said, "The concert was well attended and the talent of the performers was absolutely amazing. The concert and the silent auction allow SRC to offer 3 or 4 scholarships for children, whose parents/grandparents simply can not afford the neurosensory program, to receive this much needed therapy." One grandparent, Juanita Torres, who takes care of her twin autistic grandchildren, shared what it would mean to their family to receive a scholarship.

3 Sep 2009

Fashion show to help raise public awareness of psoriasis

Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City.

3 Sep 2009

Study reports a potential new investigational therapy for skin cancer

A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.

3 Sep 2009

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec today announced more than 70 platform and poster presentations from the company’s multiple sclerosis (MS) franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

3 Sep 2009

Volvo Cars and ALSF support families affected by pediatric cancer

Volvo Cars of North America (VCNA) is teaming up with Alex's Lemonade Stand Foundation (ALSF) during National Childhood Cancer Awareness Month to help families gain easier access to care and clinical trials at hospitals outside of their hometown.

3 Sep 2009

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

Novel oncology therapeutic evaluation in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

3 Sep 2009

National Cancer Institute awards grant to Receptor Logic for breast cancer research

Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled “Therapeutic Effectiveness of T-Cell Receptor mimic (TCRm™) Antibodies in Breast Cancer Treatment” will accelerate Investigational New Drug Application enabling studies surrounding lead candidate TCRm antibodies.

3 Sep 2009